Sign up USA
Proactive Investors - Run By Investors For Investors

Aethlon Medical soars after FDA fast-tracks its virus treatment device

The FDA fast-track program was established to speed up patient access to breakthrough technologies with the potential to address life threatening diseases for which no approved treatment alternatives exist
Blood sample
The Hemopurifier is a single-use device indicated for the treatment of life-threatening viruses

Shares in Aethlon Medical Inc (NASDAQ:AEMD) soared as the therapeutic technology company received a green light from the US Food and Drug Administration (FDA).

The shares rose 70% to US$3.39 after the company said the FDA had issued an Expedited Access Pathway (EAP) designation to support the advancement of Aethlon’s Hemopurifier device to treat life-threatening viruses.

The designation means the device will be fast-tracked through the regulatory process.

The Hemopurifier is a single-use device indicated for the treatment of life-threatening viruses that are not addressed with an approved treatment.

To date, the Hemopurifier has been validated The FDA approved Aethlon’s “indicated for use” application, meaning that rather than be used for a single disease condition, it can be used to capture a broad-spectrum of viruses, including life-threatening strains of pandemic influenza viruses, mosquito-borne viruses as well as haemorrhagic viruses that are not addressed with an approved treatment.

View full AEMD profile View Profile

Related Articles

Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
spreadsheet and calculator
January 25 2018
According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use